13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2018. See the latest, Q2 2026 →
Reported value
$614.8M
+67% on the quarter before
Positions
11
4 new · 1 sold out
Top 10
99.9%
of the value
Est. gain
+$50.1M
on stocks held all quarter
Est. return
+13.8%
on those stocks since Q4 2017
Positions as of Mar 31, 2018, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2017. Striped tiles are options.
Largest buys
Since Q4 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Zscaler~$78.3MNew · 0.0% → 12.7%+2,788,560 shares
- Arcus Biosciences Inc~$78.0MNew · 0.0% → 12.7%+5,049,786 shares
- Armo Biosciences Inc~$45.4MNew · 0.0% → 7.4%+1,214,700 shares
- Dropbox Inc~$407,000New · 0.0% → 0.1%+13,033 shares
Largest sells
Since Q4 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Cloudera Inc~$7.6MCut · 6.3% → 3.7%−353,807 shares
- Twitter Inc~$157,000Sold out · 0.0% → 0.0%−6,533 shares
Holdings
As of Mar 31, 2018. Changes are in shares against Dec 31, 2017, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arris Intl IncSHS · shares 0% · price +3.4% | 41.9% | $257.8M | +$8.5M | ||||||||
| ZscalerCOM · shares New | 12.7% | $78.3M | — | ||||||||
| Arcus Biosciences IncCOM · shares New | 12.7% | $78.0M | — | ||||||||
| Arsanis IncCOM · shares 0% · price +79.4% | 10.1% | $62.0M | +$27.4M | ||||||||
| Armo Biosciences IncCOM · shares New | 7.4% | $45.4M | — | ||||||||
| SnapCL A · shares 0% · price +8.6% | 6.8% | $41.6M | +$3.3M | ||||||||
| Cloudera IncCOM · shares −25% · price +30.6% | 3.7% | $22.9M | +$5.4M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +21.3% | 2.6% | $15.9M | +$2.8M | ||||||||
| Denali Therapeutics IncCOM · shares 0% · price +25.9% | 1.8% | $11.2M | +$2.3M | ||||||||
| BlockCL A · shares 0% · price +41.9% | 0.24% | $1.4M | +$427,000 | ||||||||
| Dropbox IncCL A · shares New | 0.07% | $407,000 | — | ||||||||
| Total · 11 positions | 100% | $614.8M | +$50.1M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2017 to Q1 2018: 7 stocks held throughout, up $50.1M (+13.8%).
- Arsanis Inc+$27.4M+79%
- Arris Intl Inc+$8.5M+3%
- Cloudera Inc+$5.4M+31%
- Snap+$3.3M+9%
- Spero Therapeutics Inc+$2.8M+21%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |